Improved Cortisol Exposure-Time Profile and Outcome in Patients with Adrenal Insufficiency: A Prospective Randomized Trial of a Novel Hydrocortisone Dual-Release Formulation
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
CONTEXT: Patients with treated adrenal insufficiency (AI) have increased morbidity and mortality rate. Our goal was to improve outcome by developing a once-daily (OD) oral hydrocortisone dual-release tablet with a more physiological exposure-time cortisol profile. OBJECTIVE: The aim was to compare pharmacokinetics and metabolic outcome between OD and the same daily dose of thrice-daily (TID) dose of conventional hydrocortisone tablets. DESIGN AND SETTING: We conducted an open, randomized, two-period, 12-wk crossover multicenter trial with a 24-wk extension at five university hospital centers. PATIENTS: The trial enrolled 64 adults with primary AI; 11 had concomitant diabetes mellitus (DM). INTERVENTION: The same daily dose of hydrocortisone was administered as OD dual-release or TID. MAIN OUTCOME MEASURE: We evaluated cortisol pharmacokinetics. RESULTS: Compared with conventional TID, OD provided a sustained serum cortisol profile 0-4 h after the morning intake and reduced the late afternoon and the 24-h cortisol exposure. The mean weight (difference = -0.7 kg, P = 0.005), systolic blood pressure (difference = -5.5 mm Hg, P = 0.0001) and diastolic blood pressure (difference: -2.3 mm Hg; P = 0.03), and glycated hemoglobin (absolute difference = -0.1%, P = 0.0006) were all reduced after OD compared with TID at 12 wk. Compared with TID, a reduction in glycated hemoglobin by 0.6% was observed in patients with concomitant DM during OD (P = 0.004). CONCLUSION: The OD dual-release tablet provided a more circadian-based serum cortisol profile. Reduced body weight, reduced blood pressure, and improved glucose metabolism were observed during OD treatment. In particular, glucose metabolism improved in patients with concomitant DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, whereas this dual-release hydrocortisone preparation was shown to slightly reduce blood pressure and HbA1c (104), such results may not always be desirable in patients with PAI.”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [104]
In the citing paper
“Dual and slowrelease formulations of cortisol may better mimic circadian hormone release (104) but do not mimic the physiological pulsatile release of cortisol.”
From Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [104]
In the citing paper
“In men with CAH, gonadal and reproductive function are often impaired due to primary gonadal failure from TARTs and/or secondary gonadal failure due to suppressed hypothalamicpituitary-gonadal axis as a consequence of high adrenal androgen concentrations (378,437,438,625).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
In the citing paper
“The reported prevalence of TARTs in CAH ranges from 14% to 86% (437,634), with an average of 25% in adolescents, and 46% in men (378).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
In the citing paper
“TARTs are benign testicular tumors typically found in males with classic CAH (378,437).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [378]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1992) · PubMed · Cited by 33,716
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402 · cited 1×
“Also, patients with hypopituitarism have a doubled standardized mortality rate (6, 7), and young adults with AI as part of their hypopituitarism have a 7-fold excessive mortality rate (8).”
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006 · cited 1×
“Also, patients with hypopituitarism have a doubled standardized mortality rate (6, 7), and young adults with AI as part of their hypopituitarism have a 7-fold excessive mortality rate (8).”
Self-citationVgontzas, A. N., Bixler, E. O., Lin, H.-M., Prolo, P., Mastorakos, G., Vela-Bueno, A., Kales, A., & Chrousos, G. P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7778 · Cited by 884 · cited 1×
“When targeting a physiological S-cortisol profile, it should also be considered that although collection of normative data has been done with care (27), there is still a concern that nighttime cortisol levels might be falsely high due to an arousal effect (stress) (28).”
(1984) · Medical Entomology and Zoology · Cited by 741
Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease
Wei, L., MacDonald, T. M., & Walker, B. R. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00007 · Cited by 730 · cited 1×
“There is a delicate balance between the short-term benefits on well-being and the long-term adverse metabolic and cognitive impact of slight cortisol overexposure as seen in subclinical Cushing’s syndrome (23) and in users of moderate doses of synthetic glucocorticoids (24).”
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0076 · Cited by 490 · cited 2×
“Studies in patients with AD have shown a more than double the standardized mortality rate (4, 5) despite contemporary optimal glucocorticoid replacement therapy.”
Self-citationRossi, R. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.4.1440 · Cited by 419 · cited 1×
“There is a delicate balance between the short-term benefits on well-being and the long-term adverse metabolic and cognitive impact of slight cortisol overexposure as seen in subclinical Cushing’s syndrome (23) and in users of moderate doses of synthetic glucocorticoids (24).”
Hahner, S., Loeffler, M., Bleicken, B., Drechsler, C., Milovanovic, D., Fassnacht, M., Ventz, M., Quinkler, M., & Allolio, B. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0884 · Cited by 346 · cited 2×
“This may be higher than reported in a previous cross-sectional survey (10) studying the frequency of adrenal crises only.”
Filipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321 · cited 7×
“Oral hydrocortisone in daily divided doses is the most widely used glucocorticoid in cortisol replacement therapy (2, 3), but no formal studies of its safety and efficacy have been performed in patients with AI.”
InfluentialSelf-citation
Cited by
Items 101–200 of 328
Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy
Dineen, R., Stewart, P. M., & Sherlock, M. (2019) · Clinical Endocrinology · doi:10.1111/cen.13837 · Cited by 30
Self-citationHealth-related quality of life in primary and secondary adrenal insufficiency
Aulinas, A., & Webb, S. M. (2014) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2014.963559 · Cited by 32
“HC treatment, 92% of patients chose to continue into the extension phase of the trial [61].”
BackgroundGuarnotta, V., Ciresi, A., Pillitteri, G., & Giordano, C. (2018) · Clinical Endocrinology · doi:10.1111/cen.13554 · Cited by 29
Novel treatments for congenital adrenal hyperplasia
Schröder, M. A. M., & der Grinten, H. L. C. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09717-w · Cited by 35
Ross, I. L., Bergthorsdottir, R., Levitt, N., Dave, J. A., Schatz, D., Marais, D., & Johannsson, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090768 · Cited by 29
Self-citationImproved salivary cortisol rhythm with dual-release hydrocortisone
Ceccato, F., Selmin, E., Sabbadin, C., Costa, M. D., Antonelli, G., Plebani, M., Barbot, M., Betterle, C., Boscaro, M., & Scaroni, C. M. (2018) · Endocrine Connections · doi:10.1530/ec-18-0257 · Cited by 32
Behan, L.-A., Carmody, D., Rogers, B., Hannon, M. J., Davenport, C., Tormey, W., Smith, D., Thompson, C. J., Stanton, A., & Agha, A. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1187 · Cited by 28
Lightman, S., & Terry, J. R. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70182-7 · Cited by 28
Health-related quality of life in children with congenital adrenal hyperplasia
Halper, A., Hooke, M. C., Gonzalez‐Bolanos, M. T., Vanderburg, N., Tran, T. N., Torkelson, J. L., & Sarafoglou, K. (2017) · Health and Quality of Life Outcomes · doi:10.1186/s12955-017-0769-7 · Cited by 33
“Circadian hydrocortisone delivery has been shown to improve QoL in adults with adrenal insufficiency and CAH [15, 16].”
BackgroundModified-Release Hydrocortisone: Is It Time to Change Clinical Practice?
Stewart, P. M. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00046 · Cited by 30
“The original randomized clinical trial [9] (n 5 64; 12 weeks’ duration), which compared this modified-release preparation with immediate-release hydrocortisone, demonstrated weight reduction and improvement in glucose tolerance, blood pressure, and quality of life scores for patients receiving the new preparation.”
BackgroundSelf-citationNegri, M., Pivonello, C., Simeoli, C., Gennaro, G. D., Venneri, M. A., Sciarra, F., Ferrigno, R., de Angelis, C., Sbardella, E., Martino, M. C. D., et al. (2020) · Neuroendocrinology · doi:10.1159/000512685 · Cited by 27
Liu, P. Y., Lawrence-Sidebottom, D., Piotrowska, K., Zhang, W., Iranmanesh, A., Auchus, R. J., Veldhuis, J. D., & Van Dongen, H. P. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab375 · Cited by 28
Johannsson, G., Lennernäs, H., Marelli, C., Rockich, K. T., & Skrtic, S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1212 · Cited by 29
Self-citationCircadian Clocks and the Interaction between Stress Axis and Adipose Function
Kolbe, I., Dumbell, R., & Oster, H. (2015) · International Journal of Endocrinology · doi:10.1155/2015/693204 · Cited by 30
“[165–167].”
What is the best approach to tailoring hydrocortisone dose to meet patient needs in 2012?
Debono, M., & Ross, R. J. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12117 · Cited by 30
Nofal, A. A., Bancos, I., Benkhadra, K., Ospina, N. S., Javed, A., Kapoor, E., Muthusamy, K., Brito, J. P., Turcu, A. F., Wang, Z., et al. (2016) · Endocrine Practice · doi:10.4158/ep161428.or · Cited by 29
Clinical Unmet Needs in the Treatment of Adrenal Crisis: Importance of the Patient’s Perspective
Claessen, K. M. J. A., Andela, C. D., Biermasz, N. R., & Pereira, A. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.701365 · Cited by 33
Glycometabolic Alterations in Secondary Adrenal Insufficiency: Does Replacement Therapy Play a Role?
Graziadio, C., Hasenmajer, V., Venneri, M. A., Gianfrilli, D., Isidori, A. M., & Sbardella, E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00434 · Cited by 24
“In particular, the od-MRHC treatment has been demonstrated to have a positive effect on body weight and glycosilated hemoglobin (HbA1c) in patients with PAI (17, 53).”
BackgroundBehan, L.-A., Kelleher, G., Hannon, M. J., Brady, J. J., Rogers, B., Tormey, W., Smith, D., Thompson, C. J., McKenna, M. J., & Agha, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0596 · Cited by 23
Daily Glucocorticoid Replacement Dose in Adrenal Insufficiency, a Mini Review
Caetano, C. M., & Malchoff, C. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.897211 · Cited by 29
Kelly, M. R., Yuen, F., Satterfield, B. C., Auchus, R. J., Gaddameedhi, S., Dongen, H. P. A. V., & Liu, P. Y. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac153 · Cited by 22
“…controlled trials show that better mimicking the diurnal rhythmicity of cortisol further optimized weight, blood pressure and glucose metabolism [14], and replicating both pulsatile and diurnal rhythmicity further improved working memory and caused subtle differences in the neural processing of…”
BackgroundBuning, J. W., Brummelman, P., Koerts, J., Dullaart, R. P. F., van den Berg, G., van der Klauw, M. M., Tucha, O. M., Wolffenbuttel, B. H. R., & van Beek, A. P. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.02.001 · Cited by 26
Olsson, D. S., Bryngelsson, I., & Ragnarsson, Ó. (2016) · Pituitary · doi:10.1007/s11102-016-0764-8 · Cited by 24
“This includes constantly improving imaging techniques, establishment of growth hormone as a part of the replacement therapy regime, and adjustment of the glucocorticoid replacement therapy towards a near-physiological pattern [10–13].”
MethodEkbom, K., Strandqvist, A., Lajić, S., Hirschberg, A. L., Falhammar, H., & Nordenström, A. (2022) · Clinical Endocrinology · doi:10.1111/cen.14676 · Cited by 23
“Hydrocortisone has a short plasma half‐life, which means that multiple doses are required throughout the day to achieve sufficient cortisol levels.(30) Prednisolone may be beneficial in patients with low adherence as it only requires one or two doses daily, due to its longer plasma half‐ life.”
BackgroundFuture Directions for Adrenal Insufficiency: Cellular Transplantation and Genetic Therapies
Graves, L. E., Torpy, D. J., Coates, P. T., Alexander, I. E., Bornstein, S. R., & Clarke, B. M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac751 · Cited by 24
Cardio‐metabolic consequences of glucocorticoid replacement: relevance of ultradian signalling
Henley, D., & Lightman, S. L. (2014) · Clinical Endocrinology · doi:10.1111/cen.12422 · Cited by 25
Šimůnková, K., Jovanovic, N., Rostrup, E., Methlie, P., Øksnes, M., Nilsen, R. M., Hennø, H., Tilseth, M., Godang, K., Kovac, A., et al. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0630 · Cited by 28
Watanabe, T., Ozawa, A., Ishii, S., Tomaru, T., Shibusawa, N., Saito, T., Yamada, E., Horiguchi, K., Nakajima, Y., Matsumoto, S., et al. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej16-0387 · Cited by 22
Improving glucocorticoid replacement profiles in adrenal insufficiency
Choudhury, S., Lightman, S. L., & Meeran, K. M. (2019) · Clinical Endocrinology · doi:10.1111/cen.13999 · Cited by 26
Improving outcomes in patients with adrenal insufficiency: a review of current and future treatments
Johannsson, G., Skrtic, S., Lennernäs, H., Quinkler, M., & Stewart, P. M. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.925865 · Cited by 21
Self-citationThe Chronobiology of Hormone Administration: “Doctor, What Time Should I Take My Medication?”
Colonnello, E., Graziani, A., Rossetti, R., Voltan, G., Masi, D., Lubrano, C., Mariani, S., Watanabe, M., Isidori, A. M., Ferlin, A., et al. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf013 · Cited by 28
A miniaturized in vitro release method for investigating drug-release mechanisms
Ahnfelt, E., Sjögren, E., Axén, N., & Lennernäs, H. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.03.076 · Cited by 22
“and development of novel DDSs where a specifically designed drug-release profile is needed to target specific pharmacodynamic and safety properties (Johannsson et al., 2011; Selen et al., 2014; Siepmann and Siepmann, 2012; Sjögren et al., 2014).”
BackgroundSelf-citationNocturnal hypoglycaemia in ACTH and GH deficient children: role of continuous glucose monitoring
Cambiaso, P., Schiaffini, R., Pontrelli, G., Carducci, C., Ubertini, G., Crea, F., & Cappa, M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12123 · Cited by 21
The management of glucocorticoid deficiency: Current and future perspectives
Dineen, R., Martin‐Grace, J., Thompson, C. J., & Sherlock, M. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.006 · Cited by 21
Recent Advances in Hydrocortisone Replacement Treatment
Mallappa, A., & Debono, M. (2015) · Endocrine development · doi:10.1159/000439329 · Cited by 22
A Contemporary Approach to the Diagnosis and Management of Adrenal Insufficiency
Charoensri, S., & Auchus, R. J. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1894 · Cited by 28
“There have been reports of favorable metabolic effects, including impacts on weight, blood pressure, glucose levels, lipid profiles, and immune cell profiles, in patients using Plenadren [44-47].”
BackgroundAuer, M. K., Stalla, G. K., & Stieg, M. R. (2016) · Pituitary · doi:10.1007/s11102-016-0726-1 · Cited by 22
“In the entire study population FLI correlated with female sex (r = -0.313; p = 0.001), Hb1Ac (r = 0.328; p = 0.001), fasting glucose (r = 0.404; p\ 0.001), HDL (r = -0.425; p\ 0.001), BMI (r = 0.852; p\ 0.001), GGT (r = 0.499; p[ 0.001), triglycerides (r = 0.456; p\ 0.001), systolic (r = 0.332; p\ 0.001) and diastolic…”
BackgroundInfluentialGroup 4: Replacement therapy for adrenal insufficiency
Castinetti, F., Guignat, L., Bouvattier, C. M., Samara‐Boustani, D., & Reznik, Y. (2017) · Annales d Endocrinologie · doi:10.1016/j.ando.2017.10.007 · Cited by 20
Adi‐Dako, O., Bekoe, S. O., Ofori-Kwakye, K., Appiah, E., & Peprah, P. (2017) · Journal of Pharmaceutics · doi:10.1155/2017/9495732 · Cited by 19
MANAGEMENT OF ENDOCRINE DISEASE: Regenerative therapies in autoimmune Addison’s disease
Gan, E. H., & Pearce, S. H. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0581 · Cited by 20
The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events
Mytareli, C., Ziogas, D. C., Karampela, A., Papalexis, P., Siampanopoulou, V., Lafioniatis, A., Benopoulou, Ο., Gogas, H. J., & Angelousi, A. G. (2023) · Cancers · doi:10.3390/cancers15072016 · Cited by 20
“Thus, it is recommended to initiate hydrocortisone at a dose of 15–25 mg or cortisone acetate 20–30 mg divided into two or three daily doses or a dual-release hydrocortisone tablet 20 mg once daily [47].”
Panigrahi, S. K., Toedesbusch, C. D., McLeland, J., Lucey, B. P., & Wardlaw, S. L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz274 · Cited by 20
Salivary Cortisol day curves in assessing glucocorticoid replacement therapy in Addison’s disease
Smans, L. C. C. J., Lentjes, E. G. W. M., Hermus, A. R., & ZELISSEN, P. M. J. (2013) · HORMONES · doi:10.1007/bf03401290 · Cited by 17
Management of congenital adrenal hyperplasia in childhood
Kim, M. S., Ryabets‐Lienhard, A., & Geffner, M. E. (2012) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835a1a1b · Cited by 19
“Unaut 1752-296X 2012 Wolters Kluwer Health | Lippincott Williams & Wilki pharmacokinetics desired for patients with CAH would differ, another dual-release formulation of hydrocortisone, Plenadren (DuoCort/ViroPharma, Helsingborg, Sweden), was tested in a European prospective, cross-over study of patients with adrenal…”
BackgroundSex-Specific Limitations in Physical Health in Primary Adrenal Insufficiency
Didriksen, N. M., Sævik, Å. B., Sortland, L. S., Øksnes, M., & Husebye, E. S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718660 · Cited by 17
“In short, there was a predominance of female patients (61%) and autoimmune etiology (84%); the median age group was 50-59 years, and the median disease duration 11 [4-24] years.”
BackgroundImitating the cortisol profile improves the immune system
Müller, L., & Quinkler, M. O. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.5 · Cited by 16
Iqbal, K., Halsby, K., Murray, R. D., Carroll, P., & Petermann, R. (2018) · Endocrine Connections · doi:10.1530/ec-18-0418 · Cited by 17
Wolf, P. S., Mayr, J., Beiglböck, H., Fellinger, P., Winhofer, Y., Poglitsch, M., Gessl, A., Kautzky‐Willer, A., Luger, A., & Krebs, M. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0086 · Cited by 16
Current and emerging therapies for Addison's disease
Napier, C., & Pearce, S. H. S. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000067 · Cited by 17
Khanna, A., Khurana, R., Kyriacou, A., Davies, R., & Ray, D. W. (2015) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-15-0005 · Cited by 18
The Adrenal Cortex and Its Disorders
Hughes, C. R., Man, E., & Achermann, J. C. (2019) · Wiley eBooks · doi:10.1002/9781119152712.ch9 · Cited by 19
Kraus, A., Penna-Martinez, M., Shoghi, F., Meyer, G., & Badenhoop, K. W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583709 · Cited by 33
Bouki, K., Venetsanaki, V., Chrysoulaki, M., Pateromichelaki, A., Betsi, G., Daraki, V. N., Sbyrakis, N., Spanakis, K., Bertsias, G. K., Sidiropoulos, P. I., et al. (2023) · HORMONES · doi:10.1007/s42000-023-00463-5 · Cited by 18
Espiard, S., McQueen, J., Sherlock, M., Ragnarsson, Ó., Bergthorsdottir, R., Burman, P., Dahlqvist, P. M., Ekman, B., Engström, B. E., Skrtic, S., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa862 · Cited by 15
“The DR-HC formulation has been studied in primary and secondary adrenal insufficiency with improvement observed in cardiovascular risk factors (eg, glucose metabolism, body weight, waist circumference) as well as in quality of life (11, 23-25).”
BackgroundMethodSelf-citationDineen, R., Martin‐Grace, J., Ahmed, K. M. S., TAYLOR, A. E. R., Shaheen, F., Schiffer, L., Gilligan, L. C., Lavery, G. G., Frizelle, I. M., Gunness, A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad370 · Cited by 14
Self-citationCeccato, F., Barbot, M., Lizzul, L., Selmin, E., Saller, A., Albiger, N. M. E., Betterle, C., Boscaro, M., & Scaroni, C. M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13490 · Cited by 15
The use of prednisolone versus dual-release hydrocortisone in the treatment of hypoadrenalism
Choudhury, S., Tan, T., Lazarus, K., & Meeran, K. M. (2021) · Endocrine Connections · doi:10.1530/ec-20-0473 · Cited by 17
Delle Cese, F., Corsello, A., Cintoni, M., Locantore, P., Pontecorvi, A., Corsello, S. M., & Paragliola, R. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.610904 · Cited by 13
“In particular, weight reduction and improvements in glucose profile and blood pressure have been reported (10).”
BackgroundRare forms of genetic paediatric adrenal insufficiency: Excluding congenital adrenal hyperplasia
Hasenmajer, V., Ferrigno, R., Minnetti, M., Pellegrini, B., Isidori, A. M., Lenzi, A., Salerno, M., Cappa, M., Chan, L. F., Martino, M. C. D., et al. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09784-7 · Cited by 24
Bioletto, F., Sibilla, M., Gasco, V., Ghigo, E., & Grottoli, S. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02356-9 · Cited by 14
“Replacement therapies have evolved and developed in the past decades, with the aim of being as close to normal physiology as possible, mimicking circadian rhythm and trying to avoid under/over treatment [39, 40].”
BackgroundPrimary adrenal insufficiency in adults: When to suspect, how to diagnose and manage
Lundholm, M. D., Ambalavanan, J., & Rao, P. P. R. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23072 · Cited by 14
“34,35 These formulations are not widely used yet and are undergoing ongoing study.”
BackgroundCan side effects of steroid treatments be minimized by the temporal aspects of delivery method?
Russell, G. M., & Lightman, S. L. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.965141 · Cited by 12
“This preparation, however, is still unable to mimic the anticipatory early morning rise of cortisol [100].”
BackgroundMethodInfluentialPlasma renin levels are associated with cardiac function in primary adrenal insufficiency
Wolf, P. S., Beiglböck, H., Fellinger, P., Pfleger, L., Aschauer, S., Gessl, A., Marculescu, R., Trattnig, S., Kautzky‐Willer, A., Luger, A., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01974-1 · Cited by 14
“In contrast to conventional therapy, when GC is administered two to three times daily to mimic the physiological cortisol rhythm, studies investigating modified-release preparations of hydrocortisone report significant improvements in body mass index (BMI), glucose, and lipid metabolism [6, 7].”
BackgroundBlacha, A. K., Kropp, P. A., Rahvar, A., Flitsch, J., van de Loo, I., & Harbeck, B. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02731-y · Cited by 12
Guarnotta, V., Amodei, R., & Giordano, C. S. D. S. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.07.003 · Cited by 14
Westeinde, A. V., Ström, S., Hirvikoski, T., Dahlqvist, P. M., Wahlberg, J., Gezelius, A., Kämpe, O., Bensing, S., & Lajić, S. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105714 · Cited by 12
Self-citationDual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review
Mongioì, L. M., Condorelli, R. A., Barbagallo, F., Vignera, S. L., & Calogero, A. E. (2020) · Endocrine · doi:10.1007/s12020-020-02187-7 · Cited by 15
Increased mortality in primary adrenal insufficiency: a systematic review and meta-analysis
Dalakas, K., Allosso, F., Basile, C., Bergthorsdottir, R., Chantzichristos, D., Hessman, E., Nwaru, B. I., Bobbio, E., Pasquali, D., Johannsson, G., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf186 · Cited by 13
Self-citationGasco, V., Giannelli, J., Campioni, L., Arvat, E., Ghigo, E., Grottoli, S., Maccario, M., & Giordano, R. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01940-1 · Cited by 12
“Finally, we have confirmed the previously reported improvement in HRQoL associated with DR-HC therapy [7, 9, 10, 15, 39, 40].”
BackgroundResultInfluentialHasenmajer, V., Ferrari, D., Alcubierre, D. D., Sada, V., Puliani, G., Bonaventura, I., Minnetti, M., Tomaselli, A., Pofi, R., Sbardella, E., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad151 · Cited by 11
“Two modified-release hydrocortisone tablets have entered the market as new formulations that better mimic cortisol secretion’s circadian rhythm [31].”
BackgroundDual-release hydrocortisone and its benefits on cognitive function and quality of sleep
Krekeler, C., Kropp, P. A., Blacha, A. K., Rahvar, A., & Harbeck, B. (2021) · Endocrine · doi:10.1007/s12020-020-02552-6 · Cited by 13
Barthel, A., Willenberg, H. S., Grüber, M., & Bornstein, S. R. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00102-5 · Cited by 12
Steroid-Induced Iatrogenic Adrenal Insufficiency in Children: A Literature Review
Akahoshi, S., & Hasegawa, Y. (2020) · Endocrines · doi:10.3390/endocrines1020012 · Cited by 10
“New oral hydrocortisone drugs that allow sustained absorption through delayed or biphasic release are being developed as a promising method of mimicking the physiological cortisol profile [86,87].”
MethodPatients with adrenal insufficiency have cardiovascular features associated with hypovolemia
Espósito, D., Bobbio, E., Fraia, R. D., Mone, P., Accardo, G., Bellis, A. D., Iorio, S., Esposito, K., Marfella, R., Johannsson, G., et al. (2020) · Endocrine · doi:10.1007/s12020-020-02458-3 · Cited by 12
“Indeed, the novel replacement treatment has an immediate-release coating and an extended-release core that better mimics the circadian rhythm of cortisol [15, 43, 44], that in turn could have beneficial effects on the circadian blood pressure profile.”
BackgroundSelf-citationLong-term effects of treatment of pituitary adenomas
Pereira, A. M. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59602-4.00024-1 · Cited by 11
Adi‐Dako, O., Ofori-Kwakye, K., Boakye-Gyasi, M. E., Bekoe, S. O., & Okyem, S. (2017) · Journal of Drug Delivery · doi:10.1155/2017/8284025 · Cited by 13
“A once daily hydrocortisone tablet with biphasic release properties produced a circadian-based serum cortisol profile relative to the conventional hydrocortisone dosage form [13, 14].”
MethodBoesen, V. B., Borresen, S. W., Christoffersen, T., Klose, M., Watt, T., & Feldt‐Rasmussen, U. (2020) · Endocrine · doi:10.1007/s12020-020-02507-x · Cited by 11
Disorders of the adrenal cortex
Sherlock, M., & Gurnell, M. (2020) · doi:10.1093/med/9780198746690.003.0249 · Cited by 10
Extended-release Hydrocortisone Formulations—Is There a Clinically Meaningful Benefit?
Steintorsdottir, S. D., Øksnes, M., Jørgensen, A. P., & Husebye, E. S. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae822 · Cited by 14
Adrenocortical stem cells in health and disease
Chu, Y., Setayesh, J., Dumontet, T., Krumeich, L. N., Werner, J., Moretti, I. F., Sousa, K. D., Kennedy, C., LaPensee, C. R., Lerário, A. M., et al. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01091-2 · Cited by 11
“Fortunately, new, oral modified-release hydrocortisone formulations such as Plenadren and Chronocort show enhanced abilities to mimic physiological cortisol levels and improve the abovementioned metabolic and cardiovascular health metrics 110–113 .”
Developing oral chronotherapy for cortisol replacement in congenital adrenal hyperplasia
Whitaker, M. J., Debono, M., & Ross, R. J. M. (2023) · Clinical Endocrinology · doi:10.1111/cen.14976 · Cited by 10
“31 The subsequent formulation approach to generating Chronocort used a conventional modified ‐ release technology platform; multiparti-culates using drug and polymer ‐ layering, to integrate the delayed ‐ and sustained ‐ release features into a revised circadian formulation of hydrocortisone.”
Kiko, N., & Kalhan, A. (2020) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000508321 · Cited by 9
Chen, A. X., & Burt, M. G. (2022) · Clinical Endocrinology · doi:10.1111/cen.14850 · Cited by 11
“In contrast, newer glucocorticoid formulations that more closely replicate circadian cortisol secretion improve insulin sensitivity compared with conventional hydrocortisone dosing.(50,51) However, there may be differences in hydrocortisone bioavailability with these preparations.”
BackgroundNovel agents to treat adrenal insufficiency: findings of preclinical and early clinical trials
Peel, A., Rushworth, R. L., & Torpy, D. J. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2311207 · Cited by 8
“It is possible that Plenadren’s benefits outlined below are due to the 20% reduction in hydrocortisone exposure associated with 1:1 Hydrocortisone:Plenadren transition [85].”
BackgroundMethodInfluentialPituitary disease mortality: is it fiction?
Erfurth, E. M., Siesjö, P., & Björk‐Eriksson, T. (2013) · Pituitary · doi:10.1007/s11102-013-0469-1 · Cited by 9
Bannon, C. A., Gallacher, D., Hanson, P., Randeva, H. S., Weickert, M. O., & Barber, T. M. (2020) · Clinical Endocrinology · doi:10.1111/cen.14275 · Cited by 8
What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study
Puglisi, S., Rossini, A., Tabaro, I., Cannavò, S., Ferraù, F., Ragonese, M., Borretta, G., Pellegrino, M., Dughera, F., Parisi, A., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01386-3 · Cited by 8
Bannon, C. A. M., Border, D., Hanson, P., Hattersley, J. G., Weickert, M. O., Grossman, A. B., Randeva, H. S., & Barber, T. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.641247 · Cited by 10
“Compared with thrice daily HC, MR-HC provides a more accurate reflection of the normal diurnal rhythm of cortisol (12), but fails to match the physiological nocturnal rise of serum cortisol (14).”
BackgroundSCHTEINGART, D. E. (2012) · Yearbook of Endocrinology · doi:10.1016/j.yend.2012.05.055 · Cited by 8
National German Audit of Diagnosis, Treatment, and Teaching in Secondary Adrenal Insufficiency
Petersenn, S., Honegger, J. B., & Quinkler, M. O. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-105077 · Cited by 10
“A modified-release preparation of HC has been developed recently as an alternative [8].”
BackgroundMortimer, B., Naganur, V., Satouris, P., Greenfield, J. R., Torpy, D. J., & Rushworth, R. L. (2020) · Clinical Endocrinology · doi:10.1111/cen.14219 · Cited by 9
Morbus Addison: Primäre Nebenniereninsuffizienz
Pulzer, A., Burger‐Stritt, S., & Hahner, S. (2016) · Der Internist · doi:10.1007/s00108-016-0054-6 · Cited by 28
“Daten kleiner Patientengruppen deuten auf ein verbessertesmetabolisches Profil und eine verbesserte Lebensqualität hin, Daten zu größeren Kollektiven liegen derzeit noch nicht vor [13, 14].”
Kendırcı, H. N. P., Ünal, E., Dündar, İ., Buluş, A. D., Güneş, S. O., & Şıklar, Z. (2024) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2024.2024-6-26-s · Cited by 11
“It has been shown that when given once a day to patients with primary adrenal insufficiency, it significantly improves metabolic variables such as body weight, body mass index and HbA1c compared to conventional HC replacement (41,42).”
Prete, A., Theiler‐Schwetz, V., Arlt, W., Hazeldine, J., Chifu, I.-O., Harbeck, B., Napier, C., Newell-Price, J. D. C., Rees, D. A., Reisch, N., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103714 · Cited by 11
“Plenadren leads to lower cortisol levels in the afternoon and evening than standard therapy, 10,11 which has been suggested to be of metabolic benefit.”
Insuficiencia suprarrenal y su tratamiento sustitutivo. Su realidad en España
Aulinas, A., Casanueva, F. F., Goñi, F., Monereo, S., Moreno, B., Pico, A. M., Puig‐Domingo, M., Salvador, J., Tinahones, F. J., & Webb, S. M. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2012.12.002 · Cited by 9
“Better results were also found in psychological function and well-being tests, and 92% of patients chose to continue on this new treatment regimen after study completion.(37) Metabolic improvements persisted during the 27-month study extension.”
BackgroundMethodResultInfluentialCapatina, C. A.-M., & Wass, J. A. H. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.11.002 · Cited by 9
Weigel, M., Hahner, S., Sherlock, M., Agha, A., Behan, L., Stewart, P. M., Arlt, W., Beier, D., Frey, K. R., Zopf, K., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13302 · Cited by 7
Self-citationHypopituitarism and Growth Hormone Deficiency
Burt, M. G., & Ho, K. K. Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00011-1 · Cited by 9
Fasting during the ramadan: a challenge for patients with adrenal insufficiency
Debono, M. (2017) · Endocrine · doi:10.1007/s12020-017-1329-y · Cited by 7
Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency
Bioletto, F., Barale, M., Parasiliti‐Caprino, M., Giannelli, J., Campioni, L., Cappiello, V., Carlo, M. C. D., Ghigo, E., Massimo, P., & Giordano, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1234237 · Cited by 8
“In recent years, a dual-release hydrocortisone (DR-HC) preparation (Plenadren ® ) was developed to maintain cortisol levels in a more physiological range, better reproducing the endogenous cortisol rhythm both when evaluated by serum cortisol (21, 22) and by salivary cortisol (23) levels.”
BackgroundResult
Metadata
- Authors
- Johannsson, G., Nilsson, A. G., Bergthorsdottir, R., Burman, P., Dahlqvist, P., Ekman, B., Engström, B. E., Olsson, T., Ragnarsson, O., Ryberg, M., Wahlberg, J., Biller, B. M. K., Monson, J. P., Stewart, P. M., Lennernäs, H., & Skrtic, S.
- Affiliations
- University of Gothenburg (SE)
- Skåne University Hospital (SE)
- Umeå University (SE)
- Linköping University (SE)
- Uppsala University Hospital (SE)
- Harvard University (US)
- St Bartholomew's Hospital (GB)
- University of Birmingham (GB)
- Uppsala University (SE)
- Corresponding author
- Johannsson, G.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-02
- Volume
- 97
- Issue
- 2
- Pages
- 473-481
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2108430953
- Semantic Scholar
- 89ffc7ce5ac189e54ea0a893bc1b71924fce41b3
- Cited by
- 329
- References
- 30
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 22 · 2023: 18 · 2022: 17 · 2021: 23 · 2020: 23 · 2019: 22 · 2018: 34 · 2017: 25 · 2016: 33 · 2015: 14 · 2014: 33 · 2013: 20 · 2012: 10
- FWCI
- 17.32
- Type
- journal article
- Language
- en
- Open access
- green
- lup.lub.lu.se
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Forskningsrådet i Sydöstra Sverige
- National Institute for Health and Care Research (NF-SI-0508-10356)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- adrenal insufficiency, cortisol, once-daily dosing, HbA1c, glucose metabolism, diabetes mellitus, blood pressure, body weight, sustained-release tablets
- MeSH terms
- Adrenal Insufficiency, Adult, Aged, Chemistry, Pharmaceutical, Delayed-Action Preparations, Female, Humans, Hydrocortisone, Male, Middle Aged, Time Factors, Treatment Outcome, Cross-Over Studies, Area Under Curve, Metabolome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.